University of Chicago Medicine Comprehensive Cancer Center

Recent papers from University of Chicago Medicine Comprehensive Cancer Center

1. ASO Reflections: Technical Success and Clinical Cost: Ethical Reflections on the Human Burden of CRS/HIPECAnnals of Surgical Oncology · 2026
2. Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)JNCI Journal of the National Cancer Institute · 2026
3. Trends in utilization of cervical cancer screening and screening-associated services in a multi-organizational research network in Chicago, Illinois, USGynecologic Oncology · 2026
4. Surgical Access and Required Transportation EscortsJAMA Surgery · 2026
5. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast CancerJournal of Clinical Oncology · 2026
6. A Full Spectrum Fibroblast Profiling Panel Reveals Phenotypic and Metabolic Heterogeneity of Cancer-Associated Fibroblasts at the Single-Cell Level2026
7. Examining the role of extrachromosomal DNA in lung cancerJNCI Journal of the National Cancer Institute · 2026
8. Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer TrialsJCO oncology advances. · 2026
9. Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologyJournal of the National Comprehensive Cancer Network · 2026
10. Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for MelanomaAmerican Society of Clinical Oncology Educational Book · 2026
11. Association of high-grade biology with marked salvage refractoriness following CD19 CAR T-cell therapy failure in large B-cell lymphoma: A systematic review and meta-analysis.Journal of Clinical Oncology · 2026
12. Knowledge of HPV-related penile cancer among U.S. men: Socioeconomic differences and divergence.Journal of Clinical Oncology · 2026
13. Association of socioeconomic and clinical factors with overall survival in immunotherapy-eligible stage III non-small cell lung cancer following definitive chemoradiation.Journal of Clinical Oncology · 2026
14. Rare histologic subtypes of triple-negative breast cancer: The impact of immunotherapy on outcomes for metastatic disease.Journal of Clinical Oncology · 2026
15. Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).Journal of Clinical Oncology · 2026
16. Hearing/vestibular dysfunction and longitudinal changes in psychosocial well-being among breast cancer survivors.Journal of Clinical Oncology · 2026
17. A Rapid Binder Discovery Workflow for Engineering Mini-Protein DegradersJournal of the American Chemical Society · 2026
18. NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026Journal of the National Comprehensive Cancer Network · 2026
19. Nanoscale Fluorescent Characterizations and Origin Tracing of Extracellular Vesicles through Standard Preparation MethodsACS Nano · 2026
20. Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyJournal of the National Comprehensive Cancer Network · 2026